Pipeline

AAVLink^TM platform, including the AAV-Find platform, the AAV-Stable platform, and the AV-Expand platform, simplifies the development of AAV vectors and expands their capabilities.

• The AAV-Find platform develops new tissue-targeted AAVs in a simple way, breaking through the barriers of animal-to-human transformation.
• The AAV-Stable platform integrates all genes required for AAV production into cells, and through induction of viral vector production, solves the current three-plasmid system, difficult amplification, high impurities and high cost.
• The AV-Expand platform establishes a highly efficient dual AAV to express genes that exceed the packaging capacity of AAV.

Protheragen is actively advancing a diverse range of gene therapy pipelines leveraging its state-of-the-art AAV vector platform. A significant milestone has been reached with the progression of the IVP-021 injection for X-linked juvenile retinoschisis (XLRS) to an investigator-initiated clinical study (IIT). The successful completion of the first subject's vitreous injection has shown promising outcomes, as the subject displayed favorable conditions within 28 days post-administration. Notably, no instances of intraocular inflammation or ocular and systemic adverse events linked to the study drug were reported. In addition, our dedicated team is actively developing several other promising pipelines designed to address a variety of gene therapies.

If you are interested in our services, please feel free to contact us for more details and quotation information of related services.